Targeting resistant cells in lung cancer treatment
Official title: Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)
Funded at University of Tx Md Anderson Can Ctr · NIH-10926884 · Data updated 2026-11-12
This study is looking at why some lung cancer cells don't respond to certain treatments and aims to find new ways to help patients get better by targeting those stubborn cells, which could lead to longer-lasting results.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 21, 2021 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $101,401 |
| NIH project number | 5R50CA265307-04 |
| Project ID | NIH-10926884 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with non-small cell lung cancer who have mutations in the EGFR gene and have experienced resistance to current TKI therapies.
✕Less likely to help
Patients with lung cancer who do not have EGFR mutations or who are not currently undergoing TKI treatment may not benefit from this research.
What this research studies
This research focuses on understanding and overcoming resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). It investigates the mechanisms behind drug-tolerant persister cells that survive initial treatments and may lead to cancer progression. The approach includes identifying novel targets and developing new drug combinations to effectively eliminate these resistant cells. Patients may benefit from improved treatment strategies that could enhance their chances of long-term remission.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer patients by overcoming drug resistance.
How similar studies have gone: Previous research has shown promise in targeting drug-resistant cancer cells, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Nilsson, Monique B — University of Tx Md Anderson Can Ctr
- Study coordinator: Nilsson, Monique B
Related research
Other NIH-funded projects on the same topics.
-
How air pollution and neighborhood stress affect lung tumors in African American patients
This project looks at whether long-term air pollution and neighborhood disadvantage change tumor DNA and short-term recurrence risk in early-stage lung cancer among African American patients.
-
Improving Immunotherapy for Lung Cancer with CT Scans
This work aims to find new ways to predict which non-small cell lung cancer patients will respond best to immunotherapy using information from their routine CT scans.
-
Targeting EGFR‑mutant lung cancer cells that resist targeted drugs
This project tests lab and translational approaches to eliminate EGFR‑mutant lung cancer cells that survive targeted drugs, for people with EGFR‑positive non‑small cell lung cancer.
-
Investigating how non-small cell lung cancer interacts with the immune system using humanized mouse models.
This study is looking at how non-small cell lung cancer interacts with the immune system using special mice that have a human-like immune system, to help understand why some patients respond well to treatments while others don’t.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.